The University of Southern California (@usc.edu)

Shortness of breath is often dismissed as aging, but for IPF patients, it can be life-threatening. @keck.usc.edu scientists are developing a regenerative drug with a $3.2M grant.

loading . . .

USC physician-scientists Denis Evseenko and Toby Maher win $3.2 million grant from the National Institute on Aging to develop regenerative drug for idiopathic pulmonary fibrosis It might start with a shortness of breath that’s easily dismissed as getting older or needing more exercise. But for the nearly 3 million patients with idiopathic pulmonary fibrosis (IPF), this subtle symptom rapidly worsens into a suffocating inability to breathe, often leading to a dangerous elevation in pulmonary artery pressure, related heart attacks or fatal respiratory failure within three to five years of diagnosis. USC physician-scientists Denis Evseenko and Toby Maher hope to offer these patients a better prognosis by developing a regenerative drug to block the cells that promote fibrosis, or scarring, in the lungs, with support from a five-year $3.2 million grant from the National Institute on Aging, part of the National Institutes of Health (NIH). https://stemcell.keck.usc.edu/physician-scientists-denis-evseenko-and-toby-maher-win-3-2-million-grant-from-the-national-institute-on-aging-to-develop-regenerative-drug-for-idiopathic-pulmonary-fibrosis/